NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | Biotech Hunter

Enrollment

187

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

April 14, 2023

Conditions

Acute Lymphoblastic LeukemiaLeukemia, Acute Myeloid (AML), ChildLymphoma, Non-HodgkinMyelodysplastic SyndromesPrimary ImmunodeficiencyAnemia, AplasticHemoglobinopathiesCytopeniaFanconi AnemiaDiamond Blackfan AnemiaThalassemiaAnemia, Sickle Cell

Interventions

DRUG

Rimiducid

Rimiducid is administered to treat chronic graft versus host disease

BIOLOGICAL

rivogenlecleucel

donor T-cells modified with iCasp safety switch

Trial Locations (1)

00161

IRCCS Ospedale Pediatrico Bambino Gesù, Rome